Calidi Biotherapeutics
CLDI
35 hedge funds and large institutions have $3.09M invested in Calidi Biotherapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 6 closing their positions.
144% more capital invested
Capital invested by funds: $1.27M → $3.09M (+$1.82M)
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
6% more funds holding
Funds holding: 33 → 35 (+2)
0.08% more ownership
Funds ownership: 0.03% → 0.11% (+0.08%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $9K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$3.16M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$453K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$277K |
| 4 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
+$237K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$87.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$157K |
| 2 |
Jane Street
New York
|
-$38.5K |
| 3 |
DWM
Drive Wealth Management
Lehi,
Utah
|
-$33.4K |
| 4 |
Goldman Sachs
New York
|
-$20.1K |
| 5 |
HF
HRT Financial
New York
|
-$18K |
CLDI Hedge Fund Activity: Q1 2025 in Review
35 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q1 2025, worth a combined $3.09M — up 144% from $1.27M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CLDI positions and 6 closed out — a net gain of 2 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $3.16M. The largest seller was Millennium Management, exiting entirely with an estimated $157K sold.
- 35 institutional investors held Calidi Biotherapeutics (CLDI) as of Q1 2025, up from 33 in Q4 2024.
- Funds reported $3.09M of Calidi Biotherapeutics stock for Q1 2025, up 144% quarter-over-quarter.
- 8 funds opened new Calidi Biotherapeutics positions in Q1 2025 and 6 closed out, a net change of +2 holders.
- The largest Calidi Biotherapeutics buyer in Q1 2025 was Armistice Capital, an estimated $3.16M added.
- The largest Calidi Biotherapeutics seller in Q1 2025 was Millennium Management, an estimated $157K sold.
Based on aggregated 13F filings for Q1 2025.